NCT01431898View on ClinicalTrials.gov

Safety, Tolerability, Pharmacokinetics and Antiviral Activity of GS-9669 in Subjects With Chronic Hepatitis C Virus Infection

PHASE1CompletedINTERVENTIONAL
Enrollment

82

Participants

Timeline

Start Date

September 30, 2011

Primary Completion Date

December 31, 2011

Study Completion Date

May 31, 2012

Conditions
Hepatitis C
Interventions
DRUG

GS-9669 tablets

DRUG

Placebo to Match GS-9669 tablet

Trial Locations (11)

19139

CRI Worldwide, Philadelphia

32720

Avail Clinical Research, LLC, DeLand

32809

Orlando Clinical Research Center, Orlando

78215

Alamo Medical Research, San Antonio

84106

Lifetree Clinical Research, LC, Salt Lake City

84132

University of Utah Health Sciences Center, Salt Lake City

89106

Impact Clinical Trials, Las Vegas

90036

Impact Clinical Trials, Los Angeles

98418

Charles River Clinical Services Northwest, Tacoma

08046

CRI Worldwide, Willingboro

00927

Fundacion de Investigacion de Diego, San Juan

Sponsors

Lead Sponsor

Gilead Sciences
All Listed Sponsors
lead

Gilead Sciences

INDUSTRY